Let’s work better together. Join us now, it's FREE! ➡️ https://bit.ly/3wQNZDg #gpcr #drgpcr

Let’s dive into the   Classified GPCR News  from July 1 to 7, 2024 GPCR Activation and Signaling GPCR-MAPK

September 2022 Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following Angiotensin 1-7 (Ang-1-7), an endogenous peptide, acts at the G protein coupled MAS1 receptors (MASR) Few studies have identified whether Ang-(1-7) decreases cognitive impairment following closed TBI. This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model

< GPCR News < GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification In this study, we elucidate the tripartite interaction between LPA-signaling, UCA1, and let-7 miRNAs Mechanistically, UCA1 sequesters let-7 miRNAs, effectively neutralizing their tumor-suppressive functions ovarian cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis -7 miRNAs , Oncogenic Pathways , Ovarian Cancer , Therapy Resistance , UCA1 , lncRNA Source Contribute

intestinal peptide receptor 2 (VIPR2) signaling suppresses cyclin D1-dependent cell-cycle progression in MCF-7 newly developed VIPR2-selective antagonist peptide, attenuated VIP-induced cell proliferation in MCF-7 The percentage of cells in the S-M phase was decreased in MCF-7 cells treated with KS-133. In MCF-7 cells stably-expressing VIPR2, KS-133 decreased PI3K activity and cAMP levels.

< GPCR News < GPCRs in Oncology and Immunology LP2, a cyclic angiotensin-(1-7) analog extended with an patient-derived xenografts of colorectal carcinoma in mice Published date February 1, 2023 Abstract " LP2 is a 4, 7 D, L lanthionine-stabilized analog of angiotensin-(1-7), with an N-terminal D-lysine, resistant to breakdown